Povidone-Iodine Plus Dexamethasone for Adenoviral Conjunctivitis
American Journal of Ophthalmology, October 2018
There are currently no approved medications for treating adenoviral conjunctivitis. Pepose et al. found a promising option in a topical ophthalmic suspension of povidone-iodine (PVP-I) 0.6% and dexamethasone 0.1%.
This multicenter, double-masked trial included 144 Indian adult patients with a positive AdenoPlus test. The researchers randomized this cohort to either PVP-I plus dexamethasone (n = 48), PVP-I alone (n = 50), or vehicle (n = 46). The 3 groups were then monitored 3, 6, and 12 days after treatment for both clinical resolution (the absence of watery conjunctival discharge and redness) and virus eradication (negative cell culture assay).
The proportion of patients with clinical resolution at the day 6 visit was 31.3% in the PVP-I–dexamethasone group, which was significantly higher than that observed in the vehicle group (10.9%) and numerically higher compared with PVP-I alone (18.0%). The results for complete eradication of the adenovirus were similar. At day 6, the proportion of patients with a negative cell culture assay was 79.2% after treatment with PVP-I plus dexamethasone, significantly higher than with vehicle (56.5%) and numerically higher compared with PVP-I alone (62.0%).
The authors also noted minimal safety concerns with the use of PVP-I plus dexamethasone. Phase 3 studies to further evaluate the safety and efficacy of this treatment are currently underway.
The original article can be found here.